Your browser is no longer supported. Please, upgrade your browser.
CBAY CymaBay Therapeutics, Inc. daily Stock Chart
CBAY [NASD]
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own0.62% Shs Outstand68.88M Perf Week-5.00%
Market Cap257.83M Forward P/E- EPS next Y-0.91 Insider Trans0.00% Shs Float68.46M Perf Month103.57%
Income-92.80M PEG- EPS next Q-0.24 Inst Own85.70% Short Float11.48% Perf Quarter123.19%
Sales- P/S- EPS this Y-22.20% Inst Trans-0.38% Short Ratio2.23 Perf Half Y123.19%
Book/sh2.54 P/B1.46 EPS next Y24.30% ROA-42.20% Target Price2.73 Perf Year-68.87%
Cash/sh2.53 P/C1.46 EPS next 5Y- ROE-45.80% 52W Range1.21 - 12.54 Perf YTD89.03%
Dividend- P/FCF- EPS past 5Y10.40% ROI- 52W High-70.45% Beta1.17
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low206.20% ATR0.32
Employees24 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)64.28 Volatility6.16% 9.02%
OptionableYes Debt/Eq0.00 EPS Q/Q49.00% Profit Margin- Rel Volume0.76 Prev Close3.92
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume3.52M Price3.70
Recom2.50 SMA2018.51% SMA5069.39% SMA20016.55% Volume2,658,320 Change-5.48%
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
May-12-20Upgrade Stifel Hold → Buy $4 → $8
May-12-20Upgrade ROTH Capital Neutral → Buy $15
May-12-20Upgrade Raymond James Mkt Perform → Outperform $7
May-12-20Upgrade Evercore ISI In-line → Outperform $15
Mar-13-20Upgrade Oppenheimer Perform → Outperform $4
Mar-13-20Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-26-19Downgrade ROTH Capital Buy → Neutral $22 → $2
Nov-26-19Downgrade Raymond James Strong Buy → Mkt Perform
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral $16 → $2
Nov-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $20 → $2
Nov-25-19Downgrade SunTrust Buy → Hold
Nov-25-19Downgrade Stifel Buy → Hold
Nov-25-19Downgrade Evercore ISI Outperform → In-line
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
Feb-06-19Initiated B. Riley FBR Neutral $9
Jun-28-18Initiated Raymond James Outperform
May-26-20 06:12PM  Is CymaBays Seladelpar Back in the Saddle? 5-Star Analyst Weighs In SmarterAnalyst
May-21-20 07:21AM  Will Good News Boost This Small-Cap Drug Company's Stock Even Higher? Motley Fool
May-15-20 08:29AM  Is CymaBay Therapeutics (CBAY) Stock a Solid Choice Right Now? Zacks
May-13-20 09:37AM  Do Options Traders Know Something About CymaBay Therapeutics (CBAY) Stock We Don't? Zacks
08:18AM  CymaBay (CBAY) Stock Is up 127% in a Day. How Much Higher Can It Go? TipRanks
May-12-20 03:20PM  Edited Transcript of CBAY earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents +127.17%
10:34AM  A Look Into CymaBay Therapeutics Price Over Earnings Benzinga
09:45AM  CymaBay Therapeutics' stock more than doubles amid hopes FDA will lift hold on NASH treatment MarketWatch
08:06AM  The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
02:20AM  CymaBay Doubles After-Hours On Positive NASH Trial Update SmarterAnalyst
02:00AM  CymaBay Therapeutics Inc (CBAY) Q1 2020 Earnings Call Transcript Motley Fool
May-11-20 04:01PM  CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
May-04-20 04:43PM  CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11 GlobeNewswire +6.51%
Apr-02-20 04:01AM  Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMT Thomson Reuters StreetEvents
Mar-20-20 08:30PM  13D Filings Barrons.com +6.87%
10:44AM  Generic Drugs Industry's Prospects Uncertain Amid Coronavirus Zacks
06:30AM  We're Keeping An Eye On CymaBay Therapeutics's (NASDAQ:CBAY) Cash Burn Rate Simply Wall St.
Mar-13-20 05:29PM  CymaBay Therapeutics Comments on Engine Capital Director Nominations Business Wire +12.77%
Mar-12-20 04:01PM  CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update GlobeNewswire -8.44%
02:30PM  CymaBay Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-11-20 07:00PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigation Possible Securities Fraud ACCESSWIRE -5.52%
Mar-10-20 12:15PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
08:44AM  Is the Options Market Predicting a Spike in CymaBay Therapeutics (CBAY) Stock? Zacks
Mar-09-20 07:51PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Investigation Into Possible Securities Fraud Ongoing GlobeNewswire
11:40AM  SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:57AM  ROSEN, A LEADING LAW FIRM, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. CBAY GlobeNewswire
Mar-06-20 10:49AM  4 Smaller, Cash-Rich Biotech Stocks That Could Be Havens Barrons.com
Mar-05-20 07:00PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud ACCESSWIRE -7.07%
04:01PM  CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12 GlobeNewswire
01:30PM  SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Mar-04-20 06:09PM  CYMABAY ALERT: Bragar Eagel & Squire, P.C. Is Investigating CymaBay Therapeutics, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
Mar-03-20 03:12PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
12:27PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud GlobeNewswire
11:00AM  CBAY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of CymaBay Therapeutics, Inc. and Encourages Investors to Contact the Firm PR Newswire
01:10AM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Mar-02-20 06:50PM  CBAY Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of CymaBay Therapeutics, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE +6.02%
06:07PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
04:15PM  EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. CBAY Business Wire
08:09AM  CymaBay Therapeutics Investigated for Possible Securities Fraud by Block & Leviton GlobeNewswire
Feb-28-20 09:52PM  HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud PR Newswire
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-29-20 04:15PM  CymaBay Publishes Shareholder Letter GlobeNewswire
Jan-15-20 02:25PM  Edited Transcript of CBAY earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Jan-10-20 09:21AM  CymaBay Therapeutics Enters Oversold Territory Zacks
Dec-31-19 11:48AM  These Falling Knives May Be Worth Catching GuruFocus.com
Dec-17-19 10:31AM  Gilead (GILD) Announces Top-Line Results From NASH Study Zacks -8.99%
Dec-10-19 03:36PM  Genfit Hopes to Buck the Odds With NASH Drug GuruFocus.com
Dec-09-19 06:09AM  Should You Take Comfort From Insider Transactions At CymaBay Therapeutics, Inc. (NASDAQ:CBAY)? Simply Wall St.
Dec-08-19 07:09PM  Is CymaBay Therapeutics Inc (CBAY) Going To Burn These Hedge Funds ? Insider Monkey
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-27-19 10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
Nov-26-19 11:07AM  Company News For Nov 26, 2019 Zacks +24.81%
08:24AM  Intercept's (ICPT) NDA for NASH Drug Gets Priority Review Zacks
08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 04:20PM  This Biotech Popped After Its Rival Crashed 76% On A Scrapped Test Investor's Business Daily -76.04%
09:14AM  UPDATE 2-CymaBay Therapeutics scraps two studies of liver drug; shares plunge Reuters
08:47AM  CymaBay Therapeutics scraps liver disease studies; shares plunge Reuters
08:34AM  CymaBay shares fall 77% on halted trial MarketWatch
08:00AM  CymaBay Therapeutics Halts Clinical Development of Seladelpar GlobeNewswire
Nov-22-19 03:22PM  3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks +6.12%
Nov-14-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-19 04:10PM  CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-19 08:00AM  CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis GlobeNewswire +8.47%
Nov-03-19 08:11AM  Is CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) CEO Salary Justified? Simply Wall St.
Oct-28-19 08:00AM  CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5 GlobeNewswire
Oct-18-19 10:23AM  These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-14-19 08:00AM  CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference GlobeNewswire
Oct-01-19 04:05PM  CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019 GlobeNewswire
Sep-30-19 08:00AM  CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-28-19 09:35AM  Investors Who Bought CymaBay Therapeutics (NASDAQ:CBAY) Shares Three Years Ago Are Now Up 168% Simply Wall St.
Sep-17-19 04:30PM  CymaBay Therapeutics Announces Departure of Chief Medical Officer GlobeNewswire
Sep-16-19 06:28AM  Investors in CymaBay Therapeutics Need Patience and Discipline TheStreet.com
Sep-10-19 03:31PM  Edited Transcript of CBAY earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-03-19 08:00AM  CymaBay Therapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-23-19 12:36PM  What You Must Know About CymaBay Therapeutics, Inc.'s (NASDAQ:CBAY) Beta Value Simply Wall St.
Aug-12-19 08:46AM  3 Hot Healthcare Stocks That Wont Break the Bank TipRanks
Aug-09-19 02:01PM  CymaBay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 04:10PM  CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-19 08:00AM  CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer GlobeNewswire -6.93%
Jul-31-19 04:23PM  CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7 GlobeNewswire
Jun-18-19 08:00AM  CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis GlobeNewswire +8.16%
Jun-17-19 02:15PM  Bulls Walk the Market Up Slowly, but Keep One Eye on Fed TheStreet.com
10:08AM  Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more American City Business Journals
08:00AM  CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-13-19 11:51AM  Hedge Funds Have Never Been This Bullish On CymaBay Therapeutics Inc (CBAY) Insider Monkey +9.40%
Jun-12-19 06:27PM  CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:53AM  CymaBay Therapeutics Stock Plunged. Heres Why It Could Be Time to Buy Barrons.com
07:34AM  The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana Benzinga
Jun-11-19 12:25PM  Here's Why CymaBay Therapeutics Collapsed Today Motley Fool -45.45%
09:02AM  How Much Are CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insiders Spending On Buying Shares? Simply Wall St.
08:58AM  CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors MarketWatch
08:30AM  CymaBay Therapeutics Plummets 40% Following Liver Disease Data Benzinga
07:00AM  CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis GlobeNewswire
Jun-10-19 02:50PM  Steven Cohen Takes an Interest in CymaBay Therapeutics GuruFocus.com
May-22-19 10:26AM  Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock Zacks
May-20-19 04:01PM  CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019 GlobeNewswire
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-16-19 09:07PM  Edited Transcript of CBAY earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah SujalChief Executive OfficerOct 10Buy4.305,00021,500120,000Oct 15 08:20 AM
Shah SujalChief Executive OfficerSep 23Buy5.553,10017,205115,000Sep 24 08:56 AM
Shah SujalChief Executive OfficerSep 20Buy5.501,90010,450111,900Sep 24 08:56 AM